XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation Suppression

Frontiers in Endocrinology
Juraj AdamikDeborah L Galson

Abstract

Multiple myeloma bone disease (MMBD) is characterized by non-healing lytic bone lesions that persist even after a patient has achieved a hematologic remission. We previously reported that p62 (sequestosome-1) in bone marrow stromal cells (BMSC) is critical for the formation of MM-induced signaling complexes that mediate OB suppression. Importantly, XRK3F2, an inhibitor of the p62-ZZ domain, blunted MM-induced Runx2 suppression in vitro, and induced new bone formation and remodeling in the presence of tumor in vivo. Additionally, we reported that MM cells induce the formation of repressive chromatin on the Runx2 gene in BMSC via direct binding of the transcriptional repressor GFI1, which recruits the histone modifiers, histone deacetylase 1 (HDAC1) and Enhancer of zeste homolog 2 (EZH2). In this study we investigated the mechanism by which blocking p62-ZZ domain-dependent signaling prevents MM-induced suppression of Runx2 in BMSC. XRK3F2 prevented MM-induced upregulation of Gfi1 and repression of the Runx2 gene when present in MM-preOB co-cultures. We also show that p62-ZZ-domain blocking by XRK3F2 also prevented MM conditioned media and TNF plus IL7-mediated Gfi1 mRNA upregulation and the concomitant Runx2 repression, indicatin...Continue Reading

References

Jun 3, 1999·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·D WangR T Franceschi
Sep 29, 1999·Genes & Development·W C DougallJ Schuh
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·J LiW J Boyle
Mar 18, 2004·Cancer Research·Shmuel YaccobyJoshua Epstein
Feb 4, 2005·The Journal of Clinical Investigation·G David Roodman, Jolene J Windle
Aug 19, 2006·Blood·Nicola GiulianiG David Roodman
Dec 19, 2006·Trends in Biochemical Sciences·Jorge MoscatMarie W Wooten
May 9, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Wei HuangYi-Ping Li
Feb 26, 2008·Journal of Biochemistry·Kayoko KawaiHiroyuki Osada
Nov 29, 2008·Leukemia·G D Roodman
Oct 24, 2009·The Journal of Biological Chemistry·Hong Bing YuB Brett Finlay
Dec 2, 2009·Advances in Experimental Medicine and Biology·Toshihisa Komori
Jan 21, 2010·BioFactors·Eric D JensenJennifer J Westendorf
Sep 24, 2010·Leukemia·L T van der MeerB A van der Reijden
Oct 15, 2011·Pediatric Rheumatology Online Journal·Ali Al KaissiFranz Grill
Nov 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michaela R Reagan, Irene M Ghobrial
Jan 6, 2012·Journal of Molecular Signaling·Stephen McManus, Sophie Roux
Jul 26, 2012·Blood Cancer Journal·S ColucciM Grano
Jan 1, 2012·BoneKEy Reports·Deborah L GalsonG David Roodman
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jan 18, 2014·Expert Review of Hematology·Evangelos TerposG David Roodman
Dec 19, 2014·Cancer Cell International·Rong FuZonghong Shao
Dec 1, 2015·Nature Cell Biology·Roshana ThambyrajahGeorges Lacaud
Jun 11, 2016·Cellular Signalling·Yu-Gang WangKe-Rong Dai
Jan 26, 2017·Molecular Cancer Research : MCR·Juraj AdamikDeborah L Galson

❮ Previous
Next ❯

Citations

Oct 28, 2019·British Journal of Pharmacology·Silvia MarinoG David Roodman
Jan 19, 2019·ACS Chemical Neuroscience·Shifan MaXiang-Qun Xie
Oct 1, 2021·Drug Discovery Today·Jacob CuylerXiang-Qun Xie

❮ Previous
Next ❯

Methods Mentioned

BETA
immunoprecipitation
FCS
PCR
ChIP
ISS
nuclear translocation
histone acetylation
acetylation

Software Mentioned

ProteinSimple AlphaView
Graphpad Prism

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.